Payment overview · 2025
General Payments
3 reported records · 3 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Family Medicine · MOUNTAIN VIEW, AR · NPI 1467459370
Verified facts
CMS Open Payments records show Ronald W Simpson, MD received $120.78 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 74.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
3 reported records · 3 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.98 | 74.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.00 | 14.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.80 | 11.4% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $120.78 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.98 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 741 | 176 |
| Pantoprazole Sodium | Pantoprazole Sodium | 543 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 512 | 122 |
| Gabapentin | Gabapentin | 448 | 110 |
| Metformin Hcl | Metformin Hcl | 346 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 334 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 331 | 86 |
| Lisinopril | Lisinopril | 280 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 255 | 56 |
| Furosemide | Furosemide | 249 | 63 |
| Meloxicam | Meloxicam | 232 | 61 |
| Potassium Chloride | Potassium Chloride | 228 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 217 | 53 |
| Omeprazole | Omeprazole | 211 | 62 |
| Losartan Potassium | Losartan Potassium | 194 | 60 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 187 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 173 | 62 |
| Mirtazapine | Mirtazapine | 157 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 52 |
| Eliquis | Apixaban | 144 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 48 |
| Prednisone | Prednisone | 136 | 91 |
| Valsartan | Valsartan | 132 | 38 |
| Sertraline Hcl | Sertraline Hcl | 123 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 123 | 32 |
| Tramadol Hcl | Tramadol Hcl | 118 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 30 |
| Glipizide | Glipizide | 104 | 31 |
| Trazodone Hcl | Trazodone Hcl | 103 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 98 | 85 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 14 |
| Ozempic | Semaglutide | 96 | 14 |
| Mounjaro | Tirzepatide | 94 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 34 |
| Simvastatin | Simvastatin | 88 | 24 |
| Allopurinol | Allopurinol | 85 | 22 |
| Montelukast Sodium | Montelukast Sodium | 82 | 22 |
| Atenolol | Atenolol | 81 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 28 |
| Farxiga | Dapagliflozin Propanediol | 72 | 13 |
| Famotidine | Famotidine | 71 | 21 |
| Finasteride | Finasteride | 70 | 17 |
| Alprazolam | Alprazolam | 69 | 18 |
| Donepezil Hcl | Donepezil Hcl | 69 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 14 |
| Carvedilol | Carvedilol | 67 | 20 |
| Cefdinir | Cefdinir | 67 | 54 |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 65 | 12 |
| Lorazepam | Lorazepam | 64 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | 13 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 15 |
| Alendronate Sodium | Alendronate Sodium | 55 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 14 |
| Celecoxib | Celecoxib | 52 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 17 |
| Spironolactone | Spironolactone | 51 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 44 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 46 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 45 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Glimepiride | Glimepiride | 42 | suppressed |
| Ondansetron Odt | Ondansetron | 42 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 23 |
| Primidone | Primidone | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Cephalexin | Cephalexin | 36 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 33 | 19 |
| Glipizide Er | Glipizide | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 22 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Metronidazole | Metronidazole | 24 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 19 |
| Nabumetone | Nabumetone | 22 | 13 |
| Naproxen | Naproxen | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Mercaptopurine | Mercaptopurine | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $120.78 · 3 records | Novo Nordisk Inc | FREESTYLE LIBRE 3, Ozempic, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error